Skip to main content

Market Overview

Perrigo's Weak Near-Term Outlook Is Concerning

Share:
Perrigo's Weak Near-Term Outlook Is Concerning

Perrigo Company plc Ordinary Shares (NYSE: PRGO) is considering the potential sale of its non-core businesses, including the lucrative royalty stream from MS drug Tysabri and the prescription pharmaceutical segment.

Argus’ Jacob Kilstein maintains a Hold rating on the company.

Concerns

Expressing concern regarding the weak near-term outlook for Perrigo, Kilstein stated that “the Tysabri sale is unwise given the drug’s outsized contribution to earnings.”

The analyst also expressed concern regarding pricing erosion and uncertainties regarding the company’s strategy.

In addition, following the departure of Perrigo’s CEO, Joseph Papa, and the sharp cut to the 2016 earnings guidance, the stock saw a pull back.

Kilstein also pointed out that “the acquisition of branded consumer health company Omega has resulted in three weak quarters, marked by heavy impairment losses. The company is also facing pricing pressure for generic drugs and increased competition in specialty medicines.”

Unwarranted Premium

On the positive side, however, the company holds a dominant position in the private-label over-the-counter pharma segment, which is quickly taking market share from branded OTC products.

Still, Kilstein believes that the stock’s premium to peers is unwarranted.

The EPS estimates for 2016 and 2017 have been lowered from $7.05 to $6.99 and from $7.76 to $7.48, respectively.

Latest Ratings for PRGO

DateFirmActionFromTo
Nov 2021Raymond JamesMaintainsOutperform
Oct 2021Raymond JamesUpgradesMarket PerformOutperform
Sep 2021JefferiesUpgradesHoldBuy

View More Analyst Ratings for PRGO

View the Latest Analyst Ratings

 

Related Articles (PRGO)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Reiteration Asset Sales Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com